What is Bicara Therapeutics's free cash flow yield?

Bicara Therapeutics (BCAX) reported free cash flow yield of -9% in Q1 2026.

How has Bicara Therapeutics's free cash flow yield changed year-over-year?

Bicara Therapeutics's free cash flow yield increased by 27.3% year-over-year, from -12.4% to -9%.

What does free cash flow yield mean?

Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.

Bicara Therapeutics BCAX Free cash flow yield

Free cash flow yield at other companies

Eli LillyLLY

1.4%+0.9pp

AmgenAMGN

4.5%-2.0pp

ImmunomeIMNM

-8.3%-3.4pp

Arcus BiosciencesRCUS

-18.1%—

Syndax PharmaceuticalsSNDX

-17.7%-3.8pp

Nuvation BioNUVB

-9%-3.6pp

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

free cash flow/market cap=-9%

Based on trailing twelve months.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's free cash flow yield?: Bicara Therapeutics (BCAX) reported free cash flow yield of -9% in Q1 2026.
How has Bicara Therapeutics's free cash flow yield changed year-over-year?: Bicara Therapeutics's free cash flow yield increased by 27.3% year-over-year, from -12.4% to -9%.
What does free cash flow yield mean?: Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.